UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 14, 2017

 


Nuvectra Corporation

(Exact Name of Registrant as Specified in its Charter)


 

 

 

 

 

 

Delaware

 

001-37525

 

30-0513847

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

  

5830 Granite Parkway, Suite 1100,

Plano, Texas 75024

(Address of principal executive offices, including zip code)

 

(214) 474-3103

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 1.01

Entry into a Material Definitive Agreement .

 

Effective February 14, 2017, Nuvectra Corporation, Algostim LLC, Pelvistim LLC and Neuronexus Technologies, Inc. (collectively, “Nuvectra”) entered into a First Amendment to its Loan and Security Agreement (the “Amendment”) with Oxford Finance LLC and Silicon Valley Bank (the “Lenders”). Pursuant to the Amendment, Nuvectra has extended the availability of its final two tranches of its credit facility by six months each and has extended and its interest-only period for Term Loan A by an additional three months if Term Loan B is not funded.

 

Under the revised terms of the Amendment, Term Loan B is now available for draw June 30, 2017 through December 31, 2017 and Term Loan C is now available for draw December 31, 2017 through June 30, 2018.

 

Under the revised terms of the Amendment, Nuvectra pays monthly accrued interest only on Term Loan A until January 1, 2018 (or April 1, 2018 if the Term Loan B Commitment is funded), and thereafter the Company will pay monthly accrued interest on Term Loan A plus equal payments of principal for 33 months (or 30 months if the Term Loan B Commitment is funded). In connection with the Amendment, Nuvectra also paid an amendment fee of $25,000 plus expenses of the Lenders.

 

The foregoing description is not complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report and incorporated by reference into this Item 1.01.

 

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits.

 

10.1

First Amendment to Loan and Security Agreement, dated February 14, 2017, among Nuvectra Corporation, Algostim LLC, Pelvistim LLC, Neuronexus Technologies, Inc. and Oxford Finance LLC and Silicon Valley Bank.

 

 

99.1

Press Release, dated February 14, 2017.  

 

 
 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

February 14, 2017  

NUVECTRA CORPORATION 

 

 

 

 

 

By: /s/ Walter Z. Berger
  Name: Walter Z. Berger
  Title:  Chief Operating Officer and Chief Financial Officer

 

Exhibit 10.1

 

FIRST AMENDMENT TO
LOAN AND SECURITY AGREEMENT

 

THIS FIRST AMENDMENT to Loan and Security Agreement (this “ Amendment ”) is entered into as of February 14, 2017, by and between OXFORD FINANCE LLC , a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“ Oxford ”), as collateral agent (in such capacity, “ Collateral Agent ”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time (each a “ Lender ” and collectively, the “ Lenders ”) including Oxford in its capacity as a Lender and SILICON VALLEY BANK , a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“ Bank ” or “ SVB ”) and NUVECTRA CORPORATION , a Delaware corporation (“ Nuvectra ”), ALGOSTIM, LLC , a Delaware limited liability company (“ Algostim ”), PELVISTIM LLC , a Delaware limited liability company (“ PelviStim ”), and NEURONEXUS TECHNOLOGIES, INC. , a Michigan corporation (“ NeuroNexus ”), each with offices located at 5830 Granite Parkway, Suite 1100, Plano, TX 75024 (Nuvectra, Algostim, PelviStim and NeuroNexus are individually and collectively, jointly and severally, “ Borrower ”).

Recitals

 

A.      Collateral Agent, Lenders and Borrower have entered into that certain Loan and Security Agreement dated as of March 18, 2016 (as amended from time to time, the “ Loan Agreement ”).

 

B.      Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement.

 

C.      Borrower has requested that Collateral Agent and Lenders (i) modify the Second Draw Period, (ii) modify the Third Draw Period and (iii) make certain other revisions to the Loan Agreement as more fully set forth herein.

 

D.      Collateral Agent and Lenders have agreed to modify such consent and to amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.

 

Agreement

 

Now, Therefore , in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

 

1.      Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.

 

2.      Amendments to Loan Agreement.

 

2.1     Section 2.2 (Term Loans) . Section 2.2(b) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

(b)      Repayment . Borrower shall make monthly payments of interest only commencing on the first (1 st ) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.4(a), and (3) a repayment schedule (i) with respect to the Term A Loans, equal to (A) thirty (30) months, if the Term B Loans are funded prior to the end of the Second Draw Period, or (B) thirty-three (33) months, if the Term B Loans are not funded prior to the end of the Second Draw Period, (ii) with respect to the Term B Loans, equal to thirty (30) months, and (iii) with respect to the Term C Loans, equal to (A) thirty (30) months, if the Term B Loans are funded prior to the end of the Second Draw Period, or (B) if the Term B Loans are not funded prior to the end of the Second Draw Period, the number of months remaining during the period commencing on the second (2 nd ) Payment Date following the Funding Date of the Term C Loans and ending on the Maturity Date. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).”

 

 
1

 

 

2.2     Section 2.6 (Fees) . New Section 2.6(f) hereby is added to the Loan Agreement to read as follows:

 

“(f)      First Amendment Fee .     A fully earned, non-refundable amendment fee of Twenty-Five Thousand Dollars ($25,000.00) (the “ First Amendment Fee ”), to be shared between the Lenders in accordance with their respective Pro Rata Shares.”

 

2.3     Section 13.1 (Definitions) . The following terms and their respective definitions hereby are added or amended and restated in their entirety, as applicable, to Section 13.1 of the Loan Agreement as follows:

 

A m orti z a ti o n D a t e ” is, (i) with respect to the Term A Loans, (A) April 1, 2018, if the Term B Loans are funded prior to the end of the Second Draw Period, or (B) January 1, 2018, if the Term B Loans are not funded prior to the end of the Second Draw Period, (ii) with respect to the Term B Loans, April 1, 2018, and (iii) with respect to the Term C Loans, (A) April 1, 2018, if the Term B Loans are funded prior to the end of the Second Draw Period, or (B) if the Term B Loans are not funded prior to the end of the Second Draw Period, the first (1 st ) Payment Date following the Funding Date of the Term C Loans.

 

Second Draw Period ” is the period (a) commencing on the later of (i) June 30, 2017 and (ii) the date of the occurrence of the Second Tranche Milestone and (b) ending on the earlier of (i) December 31, 2017, (ii) the date that is sixty (60) days after the occurrence of the Second Tranche Milestone and (iii) the occurrence of an Event of Default; provided, however, that the Second Draw Period shall not commence if on the date of the occurrence of the Second Tranche Milestone an Event of Default has occurred and is continuing.

 

Second Tranche Milestone ” is the Lenders receipt, at any time during the period from June 30, 2017 through December 31, 2017, of evidence satisfactory to the Lenders that Borrower has achieved trailing six (6) month revenues of at least Thirteen Million Five Hundred Thousand Dollars ($13,500,000.00) for the six (6) month period most recently ended.

 

Third D r aw Perio d ” is the period (a) commencing on the later of (i) December 31, 2017 and (ii) the date of the occurrence of the Third Tranche Milestone and (b) ending on the earlier of (i) June 30, 2018, (ii) the date that is sixty (60) days after the occurrence of the Third Tranche Milestone and (iii) the occurrence of an Event of Default; provided, however, that the Third Draw Period shall not commence if on the date of the occurrence of the Third Tranche Milestone an Event of Default has occurred and is continuing.

 

Third Tranche Milestone ” is the Lenders receipt, at any time during the period from December 31, 2017 through June 30, 2018, of evidence satisfactory to the Lenders that Borrower has achieved trailing six (6) month revenues of at least Twenty Million Dollars ($20,000,000.00) for the six (6) month period most recently ended.

 

 
2

 

 

3.      Limitation of Amendment.

 

3.1      The amendments set forth in Section 2 above, are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent or any Lender may now have or may have in the future under or in connection with any Loan Document.

 

3.2      This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.

 

4.      Representations and Warranties. To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:

 

4.1      Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;

 

4.2      Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;

 

4.3      The organizational documents of Borrower delivered to Collateral Agent and Lenders on the Effective Date, or subsequent thereto, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

 

4.4      The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;

 

4.5      The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;

 

4.6      The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower; and

 

4.7      This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.

 

5.      Counterparts. This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.

 

6.      Effectiveness. This Amendment shall be deemed effective upon the due execution and delivery to Collateral Agent and Lenders of (i) this Amendment by each party hereto, (ii) the due execution and delivery to Collateral Agent of the Corporate Borrowing Certificates attached hereto, (iii) the First Amendment Fee, in an amount equal to Twenty Five Thousand Dollars ($25,000.00) and (iv) Borrower’s payment of all Lenders’ Expenses incurred through the date of this Amendment.

 

 
3

 

 

In Witness Whereof, the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.

 

COLLATERAL AGENT AND LENDER:

 

OXFORD FINANCE LLC  

 

 

By:

/s/ Mark Davis  
Name: Mark Davis  
Title: Vice President, Finance  

 

 

LENDER:

 

SILICON VALLEY BANK

 

By:

/s/ Priya Lyer  
Name: Priya Lyer  
Title: Director  

 

 

BORROWER:

 

NUVECTRA CORPORATION, on behalf of itself

and all other Borrowers

 

 

By:

/s/ Walter Z. Berger  
Name: Walter Z. Berger  
Title: Chief Operating Officer and Chief Financial Officer  

   

 

 

 

[ Signature Page to First Amendment to Loan and Security Agreement ]

 

 

 

 

 

CORPORATE BORROWING CERTIFICATE

 

Borrower :

NUVECTRA CORPORATION

Date : February 14, 2017

Lenders

OXFORD FINANCE LLC, as Collateral Agent and Lender

 
 

SILICON VALLEY BANK, as Lender

 

 

I hereby certify as follows, as of the date set forth above:

 

1.     I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.

 

2.      Borrower’s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Delaware.

 

3.     Attached hereto as Exhibit A and Exhibit B , respectively, are true, correct and complete copies of (i) Borrower’s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s Bylaws. Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.

 

4.     The following resolutions were duly and validly adopted by Borrower’s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Collateral Agent and Lenders may rely on them until Collateral Agent and each Lender receives written notice of revocation from Borrower.

 

[Balance of Page Intentionally Left Blank]

 

 
 

 

 

 

Resolved , that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:

 

Name

 

Title

 

Signature

 

Authorized to

Add or Remove

Signatories

Scott F. Drees   Chief Executive Officer   /s/ Scott F. Drees  

Walter Z. Berger   Chief Operating Officer and Chief Financial Officer   /s/ Walter Z. Berger  

Melissa Beare   Secretary   /s/ Melissa Beare  

Paul Hanchin   President   /s/ Paul Hanchin  

 

Resolved Further , that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.

 

Resolved Further , that such individuals may, on behalf of Borrower:

 

Borrow Money . Borrow money from Lenders.

Execute Loan Documents . Execute any loan documents Collateral Agent or any Lender requires.

Grant Security . Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets.

Negotiate Items . Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.

Further Acts . Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions.

 

Resolved Further , that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.

 

5.     The persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.

 

   

By:

/s/ Melissa Beare
   

Name:

Melissa Beare
   

Title:

Secretary

 

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.

 

I, the Walter Z. Berger of B orrower, hereby certify as to paragraphs 1 through 5 above, as Vice President of the date set forth above.   
                                                                                                                                                                                   [print title]

 

   

By:

/s/ Walter Z. Berger
   

Name:

Walter Z. Berger
   

Title:

Vice President and Treasurer

 

 
 

 

 

EXHIBIT A

 

Certificate of Incorporation (including amendments)

 

[see attached]

 

 
 

 

   

EXHIBIT B

 

Bylaws

 

[see attached]

 

 
 

 

 

CORPORATE BORROWING CERTIFICATE

 

Borrower :

NEURONEXUS TECHNOLOGIES, INC.

Date : February 14, 2017

Lenders

OXFORD FINANCE LLC, as Collateral Agent and Lender

 
 

SILICON VALLEY BANK, as Lender

 

 

I hereby certify as follows, as of the date set forth above:

 

1.     I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.

 

2.      Borrower’s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Michigan.

 

3.     Attached hereto as Exhibit A and Exhibit B , respectively, are true, correct and complete copies of (i) Borrower’s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s Bylaws. Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.

 

4.     The following resolutions were duly and validly adopted by Borrower’s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Collateral Agent and Lenders may rely on them until Collateral Agent and each Lender receives written notice of revocation from Borrower.

 

[Balance of Page Intentionally Left Blank]

 

 
 

 

 

Resolved , that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:

 

Name

 

Title

 

Signature

 

Authorized to

Add or Remove

Signatories

           

           

           

           

 

Resolved Further , that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.

 

Resolved Further , that such individuals may, on behalf of Borrower:

 

Borrow Money . Borrow money from Lenders.

Execute Loan Documents . Execute any loan documents Collateral Agent or any Lender requires.

Grant Security . Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets.

Negotiate Items . Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.

Further Acts . Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions.

 

Resolved Further , that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.

 

5.     The persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.

 

   

By:

 
   

Name:

 
   

Title:

 

 

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.

 

I, the __________________________ of B orrower, hereby certify as to paragraphs 1 through 5 above, as                                  of the date set forth above.  
                                                                                                                                                                                                                   [print title]

 

   

By:

 
   

Name:

 
   

Title:

 

 

 
 

 

 

EXHIBIT A

 

Certificate of Incorporation (including amendments)

 

[see attached]

 

 
 

 

   

EXHIBIT B

 

Bylaws

 

[see attached]

 

 
 

 

 

LIMITED LIABILITY COMPANY BORROWING CERTIFICATE

 

Borrower :

PELVISTIM LLC

Date : February 14, 2017

Lenders

OXFORD FINANCE LLC, as Collateral Agent and Lender

 
 

SILICON VALLEY BANK, as Lender

 

 

I hereby certify as follows, as of the date set forth above:

 

1.     I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.

 

2.      Borrower’s exact legal name is set forth above. Borrower is a limited liability existing under the laws of the State of Delaware.

 

3.     Attached hereto as Exhibit A and Exhibit B , respectively, are true, correct and complete copies of (i) Borrower’s Certificate of Formation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s operating agreement. Neither such Certificate of Formation nor such operating agreement have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Formation and such operating agreement remain in full force and effect as of the date hereof.

 

4.     The following resolutions were duly and validly adopted by Borrower’s sole member and Board of Managers. Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Collateral Agent and Lenders may rely on them until Collateral Agent and each Lender receives written notice of revocation from Borrower.

 

[Balance of Page Intentionally Left Blank]

 

 
 

 

 

Resolved , that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:

 

Name

 

Title

 

Signature

Authorized to

Add or Remove

Signatories

         

         

         

         

 

Resolved Further , that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.

 

Resolved Further , that such individuals may, on behalf of Borrower:

 

Borrow Money . Borrow money from Lenders.

Execute Loan Documents . Execute any loan documents Collateral Agent or any Lender requires.

Grant Security . Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets.

Negotiate Items . Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.

Further Acts . Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions.

 

Resolved Further , that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.

 

5.     The persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.

 

   

By:

 
   

Name:

 
   

Title:

 

 

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.

 

I, the __________________________ of B orrower, hereby certify as to paragraphs 1 through 5 above, as                                  of the date set forth above.   
                                                                                                                                                                                                                   [print title]

 

 

   

By:

 
   

Name:

 
   

Title:

 

 

 
 

 

 

EXHIBIT A

 

Certificate of Formation (including amendments)

 

[see attached]

 

 
 

 

   

EXHIBIT B

 

Operating Agreement

 

[see attached]

 

 
 

 

 

LIMITED LIABILITY COMPANY BORROWING CERTIFICATE

 

Borrower :

ALGOSTIM, LLC

Date : February 14, 2017

Lenders

OXFORD FINANCE LLC, as Collateral Agent and Lender

 
 

SILICON VALLEY BANK, as Lender

 

 

I hereby certify as follows, as of the date set forth above:

 

1.     I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.

 

2.      Borrower’s exact legal name is set forth above. Borrower is a limited liability existing under the laws of the State of Delaware.

 

3.     Attached hereto as Exhibit A and Exhibit B , respectively, are true, correct and complete copies of (i) Borrower’s Certificate of Formation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s operating agreement. Neither such Certificate of Formation nor such operating agreement have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Formation and such operating agreement remain in full force and effect as of the date hereof.

 

4.     The following resolutions were duly and validly adopted by Borrower’s sole member and Board of Managers. Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Collateral Agent and Lenders may rely on them until Collateral Agent and each Lender receives written notice of revocation from Borrower.

 

[Balance of Page Intentionally Left Blank]

 

 
 

 

 

Resolved , that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:

 

Name

 

Title

 

Signature

 

Authorized to

Add or Remove

Signatories

           

           

           

           

 

Resolved Further , that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.

 

Resolved Further , that such individuals may, on behalf of Borrower:

 

Borrow Money . Borrow money from Lenders.

Execute Loan Documents . Execute any loan documents Collateral Agent or any Lender requires.

Grant Security . Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets.

Negotiate Items . Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.

Further Acts . Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions.

 

Resolved Further , that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.

 

5.     The persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.

 

   

By:

 
   

Name:

 
   

Title:

 

 

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.

 

I, the __________________________ of B orrower, hereby certify as to paragraphs 1 through 5 above, as                                   of the date set forth above.
                                                                                                                                                                                                                   [print title]

 

   

By:

 
   

Name:

 
   

Title:

 

 

 
 

 

 

EXHIBIT A

 

Certificate of Formation (including amendments)

 

[see attached]

 

 
 

 

   

EXHIBIT B

 

Operating Agreement

 

[see attached]

Exhibit 99.1

 

 

 

FOR IMMEDIATE RELEASE

 

Company Contacts:

Investor Contacts:

Nuvectra Corporation                                          The Ruth Group          
Walter Berger, Chief Operating Officer and Chief Financial Officer                                    Nick Laudico
(214) 474-3102 (646) 536-7030          
wberger@nuvectramed.com nlaudico@theruthgroup.com

 

Jennifer Armstrong, Media Relations Zack Kubow
(214) 474-3110  (646) 536-7020
jarmstrong@nuvectramed.com zkubow@theruthgroup.com

 

 

Nuvectra Extends Timeline of Existing Credit Facility

 

 

Plano, Texas, February 14 , 2017 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with the lenders of its $45 million credit facility, Silicon Valley Bank and Oxford Finance, to extend the availability of the final two tranches of the facility.

 

On March 18, 2016, the Company entered into a loan agreement with Silicon Valley Bank and Oxford Finance consisting of a $40.0 million term loan credit facility, from which $15.0 million was funded at the closing of the agreement, and a $5.0 million revolving line commitment.

 

The six-month extension on each of its Term B and Term C commitments allows the Company to draw down the second tranche worth $12.5 million by December 31, 2017, and the third and final tranche also worth $12.5 million by June 30, 2018. The original agreement made each tranche available through June 30, 2017 and December 31, 2017 respectively.

 

Walter Berger, Chief Operating Officer & Chief Financial Officer, commented, “We are very pleased to announce this six-month extension, which increases our flexibility to access additional capital in line with our needs as we grow our commercial footprint. We thank our partners at Silicon Valley Bank and Oxford Finance for their continued support, and look forward to continuing to execute our long term growth strategies.”

 

# # #

 

 

About Nuvectra Corporation
Nuvectra TM is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com .

 

 
 

 

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements," including statements we make regarding the outlook for Nuvectra as an independent publicly-traded company. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and therefore they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and may be outside of our control. Our actual performance may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include: (i) the timing of the commercial launch of Algovita in the United States; (ii) our ability to successfully commercialize Algovita and develop and commercialize enhancements to Algovita; (iii) the uncertainty of obtaining regulatory approvals in the United States and Europe for our Virtis SNS system; (iv) our ability to successfully launch and commercialize the Virtis SNS system if it receives regulatory approval; (v) the outcome of our development plans for our neurostimulation technology platform, including our ability to identify additional indications or conditions for which we may develop neurostimulation medical devices or therapies and seek regulatory approval thereof; (vi) our ability to identify business development and growth opportunities and to successfully execute on our strategy, including our ability to seek and develop strategic partnerships with third parties to, among other things, fund clinical and development costs for new product offerings; (vii) the performance by our development partners, including Aleva Neurotherapeutics, S.A., of their obligations under their agreements with us; (viii) the scope of protection for our intellectual property rights covering Algovita and other products using our neurostimulation technology platform, along with any product enhancements; (ix) our ability to successfully build an effective commercial infrastructure and sales force in the United States; (x) our compliance with all regulatory and legal requirements regarding implantable medical devices and interactions with healthcare professionals; and (xi) any product recalls or the receipt of any warning letters from any governmental or regulatory agency. Please see the sections entitled "Cautionary Statement Concerning Forward-Looking Statements" and "Risk Factors" in Nuvectra's Registration Statement on Form 10 for a description of these and other risks and uncertainties. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise